Ivabradina Chemo Ibérica

Ivabradine, the active ingredient in Ivabradina Chemo Ibérica, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients. GNH USA supplies Ivabradina Chemo Ibérica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Chemo Ibérica acts on the cardiac If current to reduce heart rate in several cardiovascular conditions. - Chronic stable angina: decreases the frequency of angina attacks by lowering myocardial oxygen demand. - Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalisations through heart‑rate reduction. - Patients intolerant to beta‑blockers: provides an alternative means of controlling heart rate without beta‑adrenergic blockade.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Phosphenes (transient visual disturbances) - Headache - Dizziness - Fatigue - Bradycardia (asymptomatic) - Nausea

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention - Atrial fibrillation or other arrhythmias - Severe hypotension - Persistent visual impairment - Worsening angina or myocardial infarction - Heart failure decompensation

Careful assessment and monitoring are required before and during therapy. - Heart rate monitoring: ensure resting heart rate remains above 50 bpm. - Severe hepatic impairment: avoid or use with caution. - Sick sinus syndrome or atrioventricular block: contraindicated. - Concomitant strong CYP3A4 inhibitors: avoid due to increased exposure. - Renal impairment: dose adjustment may be needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradina Chemo Ibérica can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may raise plasma levels. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil) – risk of excessive heart‑rate reduction. - Certain anti‑arrhythmic drugs (e.g., amiodarone) – can potentiate bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin) – monitor heart rate. - Antihypertensive agents – watch for additive blood‑pressure lowering. - Drugs affecting QT interval – observe ECG for changes. - Herbal supplements containing St. John’s wort – may reduce efficacy.